Group 1 - The core project launched by Chutian Technology for Anabion in Qatar is a large-scale biopharmaceutical initiative, marking a significant step in the company's overseas expansion strategy for 2026 [1] - Chutian Technology's subsidiaries will collaborate to develop and manufacture a complete process equipment for the project, covering upstream processes to downstream packaging and testing, enhancing capabilities in monoclonal antibody research and production [1] - The project is considered both a large-scale investment and a technological milestone, reflecting the importance of the collaboration for both Chutian Technology and its users [1] Group 2 - Anabion's founder, Morozov, emphasized that the collaboration with Chutian Technology represents a significant advancement in their partnership, contributing to the development of cutting-edge pharmaceutical technology in the region [2] - Anabion is an international biotechnology company based in Doha, Qatar, focused on providing effective, safe, and affordable solutions in the life sciences sector, particularly in drug development for oncology, autoimmune diseases, and rare diseases [2]